FindTrial
Sign In

Influence of number of adjuvant chemotherapy cycles on prognosis of patients with advanced gastric cancer

Influence of number of adjuvant chemotherapy cycles on prognosis of patients with advanced gastric cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300076891
Enrollment
Unknown
Registered
2023-10-23
Start date
2023-10-27
Completion date
Unknown
Last updated
2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

The group receiving different adjuvant chemotherapy cycles and the group without chemotherapy:NA

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 85 Years

Inclusion criteria

Inclusion criteria: stage II-III gastric cancer patients undergoing radical gastrectomy

Exclusion criteria

Exclusion criteria: (1) receiving neoadjuvant chemotherapy ; (2) remnant GC; (3) positive resection margin; (4) distant metasistasis (IV stage); (5) early stage gastric cancer(I stage)

Design outcomes

Primary

MeasureTime frame
Overall survival rate;—

Secondary

MeasureTime frame
Clinicopathological characteristics of gastric cancer patients receiving different chemotherapy cycles;Univariate and multivariate analysis of prognosis of gastric cancer;—

Countries

China

Contacts

Public ContactJiankun Hu

West China Hospital, Sichuan University

hujkwch@126.com+86 189 8060 1504

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026